Get the Stockscreener App
0.6982
3.71%
-0.0269
Pasithea Therapeutics Corp stock is traded at $0.6982, with a volume of 76,724.
It is down -3.71% in the last 24 hours and down -4.96% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$0.7251
Open:
$0.7301
24h Volume:
76,724
Relative Volume:
0.02
Market Cap:
$5.20M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0502
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-3.83%
1M Performance:
-4.96%
6M Performance:
-68.83%
1Y Performance:
-86.06%
1-Day Range:
$0.6789
$0.7301
1-Week Range:
$0.6789
$0.785
52-Week Range:
$0.65
$7.50
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(702) 514-4174
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.6982 | 5.40M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Can trapped investors hope for a rebound in Pasithea Therapeutics Corp.Free Weekly Chart Analysis With Entry Advice - Newser
Will Pasithea Therapeutics Corp. Equity Warrant stock benefit from interest rate changesLow Exposure Strategy with Sector Analysis - Newser
Does Pasithea Therapeutics Corp. Equity Warrant fit your quant trading modelShort-Term Growth Watch with Signal Prediction - Newser
Does Pasithea Therapeutics Corp. Equity Warrant stock perform well during market downturnsFinancial News Data Feed With Proven Results - jammulinksnews.com
Price action breakdown for Pasithea Therapeutics Corp. Equity WarrantWeekly Chart-Based Forecast for Traders - Newser
Long term hold vs stop loss in Pasithea Therapeutics Corp.Chart Pattern Recognition for Profit Timing - Newser
Is Pasithea Therapeutics Corp. Equity Warrant a growth stock or a value stockSwing Trade Alerts For Beginners - jammulinksnews.com
Is it the right time to buy Pasithea Therapeutics Corp. stockMarket Forecast Alerts Backed By Experts - jammulinksnews.com
Should I hold or sell Pasithea Therapeutics Corp. stock in 2025Advanced Screener Entry Points For Consistent Profits - jammulinksnews.com
What catalysts could drive Pasithea Therapeutics Corp. stock higher in 2025Best Dividend Tracker For Every Investor - jammulinksnews.com
Why Pasithea Therapeutics Corp. stock attracts strong analyst attentionSwing Trade Watchlist with Entry Zones - Newser
Can machine learning forecast Pasithea Therapeutics Corp. recoveryReal-Time Signal Tracking with Entry Level - Newser
Combining machine learning predictions for Pasithea Therapeutics Corp.Free Buy Alerts With Low Risk Confirmation - Newser
Pasithea Therapeutics Corp. Equity Warrant stock trendline breakdownInvestment Position Summary with Timeframe Forecast - Newser
Pasithea completes enrollment of first cohort in NF1 clinical trial By Investing.com - Investing.com India
Pasithea Therapeutics Completes Enrollment and Initial - GlobeNewswire
Revolutionary Once-Daily NF1 Treatment Begins Phase 1/1b Trial: First Patients Successfully Dosed - Stock Titan
Exit strategy if you’re trapped in Pasithea Therapeutics Corp. Equity WarrantRisk Shielded Trade Watch with Analysis - Newser
What does recent volatility data suggest for Pasithea Therapeutics Corp. Equity WarrantProfitable Trading Blueprint with Entry Zones - Newser
Key resistance and support levels for Pasithea Therapeutics Corp. Equity WarrantLow Volatility Stock Analysis With Confidence - Newser
How Pasithea Therapeutics Corp. Equity Warrant stock performs during market volatilityBuy Point Strategy with Profit Protection - Newser
Published on: 2025-07-30 21:59:53 - Newser
Real time breakdown of Pasithea Therapeutics Corp. Equity Warrant stock performanceLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Bollinger Band Squeeze Points to Volatility in Pasithea Therapeutics Corp.AI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
Wyckoff Accumulation Phase Possible in Pasithea Therapeutics Corp.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
Traders Watching For Reversal Pattern in Pasithea Therapeutics Corp.Daily Momentum Screener With Alerts Launched - metal.it
Can Pasithea Therapeutics Corp. Rally Enough to Break EvenAlpha Driven Watchlist With Alerts Published - metal.it
Trendline Breach Raises Concern for Pasithea Therapeutics Corp. Equity Warrant InvestorsEntry Points For Growing Stocks Identified by Models - metal.it
Volatility clustering patterns for Pasithea Therapeutics Corp.Risk-Managed Swing Setup and Signal Analysis - Newser
Visual analytics tools that track Pasithea Therapeutics Corp. performanceLow Risk Stock Selection Strategy Guide - Newser
Published on: 2025-07-29 09:59:56 - metal.it
Why Pasithea Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionFree Investment Strategy With Low Risk - Newser
What makes Pasithea Therapeutics Corp. Equity Warrant stock price move sharplyHigh Reward Picks with Tight Risk Control - Newser
How does Pasithea Therapeutics Corp. Equity Warrant generate profit in a changing economyEntry Signal Tracker For Consistent Profits - jammulinksnews.com
Published on: 2025-07-29 03:20:54 - metal.it
How strong is Pasithea Therapeutics Corp. Equity Warrant company’s balance sheetCapitalize on emerging market trends - jammulinksnews.com
How Pasithea Therapeutics Corp. stock performs during market volatilityFree Fundamental Growth Stock Analysis - Newser
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pasithea Therapeutics Corp Stock (KTTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):